Johnson & Johnson MedTech’s MONARCH Platform and MONARCH Bronchoscope have received regulatory approval in China, marking the first minimally invasive, robotic-assisted technology for peripheral lung procedures approved in China and the first J&J MedTech robotic-assisted technology approved in China, and the first regulatory approval of the MONARCH Platform outside of the United States.

Used with the MONARCH Bronchoscope, the MONARCH Platform is designed to provide bronchoscopic visualisation and access to the airways of adult patients for diagnostic and therapeutic procedures, enabling physicians to use minimally invasive, robotic-assisted technology for peripheral lung procedures.

The ability to access small, hard-to-reach peripheral lung nodules earlier and with greater precision is helping to transform the future of interventional patient care, as lung cancer nodules are typically small, deep in the lung and difficult to access, making early diagnosis and treatment challenging.

More than two million patients worldwide are diagnosed with lung cancer each year, and nearly 40% of them are in China. With this approval, MONARCH is ready to help physicians in China work with patients to fight one of the most common and deadly diseases in the country,” said Will Song, President of Johnson & Johnson MedTech China.

To view the source version, please click HERE.

en_GBEnglish (UK)